We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Allergan Sheds Brazikumab, Zenpep Ahead of AbbVie Merger
Allergan Sheds Brazikumab, Zenpep Ahead of AbbVie Merger
Allergan has agreed to sell off its investigational drug brazikumab and its pancreatic enzyme drug Zenpep (pancrelipase) to clear the way for its proposed $63 billion acquisition by AbbVie.